Frequency of the virilising effects of attenuated androgens reported by women with hereditary angioedema

Orphanet Journal of Rare Diseases

Henriette Farkas¹  Lilian Varga¹  Dorottya Csuka¹  Nóra Veszeli¹  Zsuzsanna Zotter¹ 

[1] 3rd Department of Internal Medicine, Semmelweis University, Kútvölgyi út 4, Budapest H-1125, Hungary

关键词: Side effect;    Virilization;    Danazol;    Attenuated androgen;    C1 inhibitor deficiency;    Hereditary angioedema;   

Others  :  1149262
DOI  :  10.1186/s13023-014-0205-6

 received in 2014-09-23, accepted in 2014-11-27,  发布年份 2014

【 摘 要 】

Background

Danazol, a drug extensively used in the management of hereditary angioedema due to C1 inhibitor deficiency (C1-INH-HAE), has various side effects. This study investigated the virilizing actions of this drug in 31 danazol-treated female patients with HAE-C1-INH. We compared our findings with those of healthy controls and with literature data.

Methods

The patients were interviewed individually about the type and severity of the virilizing effects, as well as about their satisfaction with danazol therapy.

Results

The average duration of danazol treatment was 10.31 years [2 to 23] and its mean daily dose was 131.7 mg [33 to 200]. The most common adverse effects were hirsutism (n = 14), weight gain (n = 13), and menstrual disturbances (n = 8). The severity of danazol adverse effects did not differ by duration of treatment or by daily drug dose. The mean level of patient satisfaction with the treatment was high. The comparison of age-matched healthy controls and of HAE-C1-INH patients receiving danazol did not demonstrate a statistically higher incidence of any of the monitored symptoms in the danazol group.

Conclusions

Our findings indicate that long-term danazol treatment – using the lowest effective dose – has only a mild virilizing effect.

【 授权许可】

   
2014 Zotter et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Cicardi M, Aberer W, Banerji A, Bas M, Bernstein JA, Bork K, Caballero T, Farkas H, Grumach A, Kaplan AP, Riedl MA, Triggiani M, Zanichelli A, Zuraw B: HAWK under the patronage of EAACI (European Academy of Allergy and Clinical Immunology): Classification, diagnosis, and approach to treatment for angioedema: consensus report from the Hereditary Angioedema International Working Group. Allergy 2014, 69:602-616.
• [2]Bork K, Meng G, Staubach P, Hardt J: Hereditary angioedema: new findings concerning symptoms, affected organs, and course. Am J Med 2006, 119:267-274.
• [3]Farkas H: Current pharmacotherapy of bradykinin-mediated angioedema. Expert Opin Pharmacother 2013, 14:571-586.
• [4]Frank MM, Gelfand JA, Atkinson JP: Hereditary angioedema: the clinical syndrome and its management. Ann Intern Med 1976, 84:580-593.
• [5]Bouillet L, Longhurst H, Boccon-Gibod I, Bork K, Bucher C, Bygum A, Caballero T, Drouet C, Farkas H, Massot C, Nielsen EW, Ponard D, Cicardi M: Disease expression in women with hereditary angioedema. Am J Obstet Gynecol 2008, 199:484. e481-484
• [6]Pappalardo E, Zingale LC, Cicardi M: Increased expression of C1-inhibitor mRNA in patients with hereditary angioedema treated with Danazol. Immunol Lett 2003, 86:271-276.
• [7]Drouet C, Désormeaux A, Robillard J, Ponard D, Bouillet L, Martin L, Kanny G, Moneret-Vautrin DA, Bosson JL, Quesada JL, López-Trascasa M, Adam A: Metallopeptidase activities in hereditary angioedema: effect of androgen prophylaxis on plasma aminopeptidase P. J Allergy Clin Immunol 2008, 121:429-433.
• [8]Fust G, Farkas H, Csuka D, Varga L, Bork K: Long-term efficacy of danazol treatment in hereditary angioedema. Eur J Clin Invest 2011, 41:256-262.
• [9]Shahidi NT: A review of the chemistry, biological action, and clinical applications of anabolic-androgenic steroids. Clin Ther 2001, 23:1355-1390.
• [10]Gelfand JA, Sherins RJ, Alling DW, Frank MM: Treatment of hereditary angioedema with danazol. Reversal of clinical and biochemical abnormalities. N Engl J Med 1976, 295:1444-1448.
• [11]Zurlo JJ, Frank MM: The long-term safety of danazol in women with hereditary angioedema. Fertil Steril 1990, 54:64-72.
• [12]Cicardi M, Castelli R, Zingale LC, Agostoni A: Side effects of long-term prophylaxis with attenuated androgens in hereditary angioedema: comparison of treated and untreated patients. J Allergy Clin Immunol 1997, 99:194-196.
• [13]Sloane DE, Lee CW, Sheffer AL: Hereditary angioedema: Safety of long-term stanozolol therapy. J Allergy Clin Immunol 2007, 120:654-658.
• [14]Bork K, Bygum A, Hardt J: Benefits and risks of danazol in hereditary angioedema: a long-term survey of 118 patients. Ann Allergy Asthma Immunol 2008, 100:153-161.
• [15]Farkas H, Czaller I, Csuka D, Vas A, Valentin S, Varga L, Széplaki G, Jakab L, Füst G, Prohászka Z, Harmat G, Visy B, Karádi I: The effect of long-term danazol prophylaxis on liver function in hereditary angioedema-a longitudinal study. Eur J Clin Pharmacol 2010, 66:419-426.
• [16]Szegedi R, Szeplaki G, Varga L, Prohaszka Z, Szeplaki Z, Karadi I, Fust G, Farkas H: Long-term danazol prophylaxis does not lead to increased carotid intima-media thickness in hereditary angioedema patients. Atherosclerosis 2008, 198:184-191.
• [17]Szeplaki G, Varga L, Valentin S, Kleiber M, Karadi I, Romics L, Fust G, Farkas H: Adverse effects of danazol prophylaxis on the lipid profiles of patients with hereditary angioedema. J Allergy Clin Immunol 2005, 115:864-869.
• [18]Zuraw BL: Hereditary angiodema: a current state-of-the-art review, IV: short- and long-term treatment of hereditary angioedema: out with the old and in with the new? Ann Allergy Asthma Immunol 2008, 100:S13-S18.
• [19]Cicardi M, Bergamaschini L, Cugno M, Hack E, Agostoni G, Agostoni A: Long-term treatment of hereditary angioedema with attenuated androgens: a survey of a 13-year experience. J Allergy Clin Immunol 1991, 87:768-773.
• [20]Zuraw BL, Busse PJ, White M, Jacobs J, Lumry W, Baker J, Craig T, Grant JA, Hurewitz D, Bielory L, Cartwright WE, Koleilat M, Ryan W, Schaefer O, Manning M, Patel P, Bernstein JA, Friedman RA, Wilkinson R, Tanner D, Kohler G, Gunther G, Levy R, McClellan J, Redhead J, Guss D, Heyman E, Blumenstein BA, Kalfus I, Frank MM: Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema. N Engl J Med 2010, 363:513-522.
• [21]Porebski G, Reshef A, Moldovan D: The prophylaxis of hereditary angioedema attacks with recombinant human C1 inhibitor: who will take advantage of the individualized treatment approach? Allergy 2013, 68:1207-1209.
• [22]Bowen T, Cicardi M, Farkas H, Bork K, Longhurst HJ, Zuraw B, Aygoeren-Pürsün E, Craig T, Binkley K, Hebert J, Ritchie B, Bouillet L, Betschel S, Cogar D, Dean J, Devaraj R, Hamed A, Kamra P, Keith PK, Lacuesta G, Leith E, Lyons H, Mace S, Mako B, Neurath D, Poon MC, Rivard GE, Schellenberg R, Rowan D, Rowe A, et al.: 2010 International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema. Allergy Asthma Clin Immunol 2010, 6:24. BioMed Central Full Text
• [23]Craig T, Aygören-Pürsün E, Bork K, Bowen T, Boysen H, Farkas H, Grumach A, Katelaris CH, Lockey R, Longhurst H, Lumry W, Magerl M, Martinez-Saguer I, Ritchie B, Nast A, Pawankar R, Zuraw B, Maurer M: WAO Guideline for the Management of Hereditary Angioedema. World Allergy Organ J 2012, 5:182-199.